Inogen (INGN) Hits New 52-Week High and Low at $144.05

Inogen (NASDAQ:INGN)’s share price hit a new 52-week high and low on Wednesday . The company traded as low as $144.05 and last traded at $142.90, with a volume of 56498 shares. The stock had previously closed at $143.32.

A number of brokerages have recently weighed in on INGN. Piper Jaffray set a $145.00 target price on Inogen and gave the stock a “buy” rating in a research note on Saturday. BidaskClub upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 6th. ValuEngine upgraded Inogen from a “hold” rating to a “buy” rating in a research note on Friday, April 6th. Needham & Company LLC reiterated a “buy” rating and issued a $150.00 price objective on shares of Inogen in a research note on Tuesday, March 27th. Finally, Zacks Investment Research downgraded Inogen from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 5th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $115.14.

How to Become a New Pot Stock Millionaire

The company has a market cap of $2,957.84, a P/E ratio of 108.41, a P/E/G ratio of 3.88 and a beta of 1.03.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, February 27th. The medical technology company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.21 by $0.10. Inogen had a return on equity of 13.47% and a net margin of 8.42%. The business had revenue of $63.79 million for the quarter, compared to the consensus estimate of $62.01 million. research analysts expect that Inogen will post 1.6 earnings per share for the current year.

In other Inogen news, EVP Brenton Taylor sold 15,000 shares of the stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $117.47, for a total transaction of $1,762,050.00. Following the sale, the executive vice president now owns 38,982 shares in the company, valued at $4,579,215.54. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Alison Bauerlein sold 27,630 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $116.46, for a total value of $3,217,789.80. Following the sale, the executive vice president now owns 11,718 shares in the company, valued at approximately $1,364,678.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,718 shares of company stock worth $13,919,791. 5.29% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of INGN. SG Americas Securities LLC purchased a new stake in shares of Inogen during the third quarter worth $213,000. Legal & General Group Plc lifted its position in shares of Inogen by 12.0% during the third quarter. Legal & General Group Plc now owns 33,188 shares of the medical technology company’s stock worth $3,155,000 after acquiring an additional 3,559 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Inogen by 8.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 77,273 shares of the medical technology company’s stock worth $7,349,000 after acquiring an additional 5,917 shares in the last quarter. Allianz Asset Management GmbH lifted its position in shares of Inogen by 3.8% during the third quarter. Allianz Asset Management GmbH now owns 40,629 shares of the medical technology company’s stock worth $3,864,000 after acquiring an additional 1,490 shares in the last quarter. Finally, California Public Employees Retirement System lifted its position in shares of Inogen by 31.2% during the third quarter. California Public Employees Retirement System now owns 26,498 shares of the medical technology company’s stock worth $2,520,000 after acquiring an additional 6,298 shares in the last quarter. Hedge funds and other institutional investors own 98.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Inogen (INGN) Hits New 52-Week High and Low at $144.05” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/18/inogen-ingn-hits-new-52-week-high-and-low-at-144-05.html.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply